HHS names four senior FDA leaders to advance technology, artificial intelligence, drug regulation, biologics oversight, and tobacco policy

The U.S. Department of Health and Human Services announced four senior leadership selections at the Food and Drug Administration on September 8, 2026. Jared Seehafer was selected as FDA’s first Deputy Commissioner for Technology and Artificial Intelligence, with responsibility for agency-wide technology, software, and AI strategy. Michael Davis was selected to lead the Center for Drug Evaluation and Research, focusing on access to affordable medicines, drug development science, and supply-chain resilience. Karim Mikhail was selected to direct the Center for Biologics Evaluation and Research, overseeing vaccines, blood products, and cellular and gene therapies while emphasizing modernization, clinical development, and safety surveillance. Bret Koplow was selected to lead the Center for Tobacco Products, balancing access to less harmful alternatives for adult smokers with protections for youth and minors. HHS presents the appointments as part of a broader agenda of innovation, reform, national health security, and public health priorities.